The ACTIV-6 trial reports that people who took the drug for three days may have spent slightly less time feeling unwell with SARS-CoV-2, but fails to find differences in disease progression between the treatment and placebo groups.

Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?

The US FDA’s decision not to grant an emergency use authorization for the antidepressant as a COVID-19 treatment highlights a lack of consensus among researchers about how to interpret clinical data on the drug.

The presence and spread of new, more-infectious and immune-evading variants show that the coronavirus is not done mutating.

A sugar that’s less abundant in the blood of people with diabetes binds to SARS-CoV-2’s spike protein and disrupts the virus’s ability to fuse with cells.  

US adults are now only eligible for the vaccine under certain circumstances.

Studies suggest SARS-CoV-2 infection could trigger the development of diabetes in some people, even those with no other risk factors.

Officials have ruled out known hepatitis viruses as the cause of a rash of illnesses in Europe and the US.

The Scientist spoke with Ohio State University microbiologist Matthew Sullivan about a recent expedition that identified thousands of RNA viruses from water samples and cataloged them into novel phylogenic groups.

A new presidential memorandum requires the Department of Health and Human Services to coordinate a government-wide push to generate a research action plan for the condition.

The virus’s ability to slip directly from one cell to another may help it avoid some of the body’s immune responses.

In addition to causing more frequent natural disasters, global warming can have long-term health effects, which range from heat stress to mosquito-borne disease.

The first part of 2022 is giving us a glimpse of humanity’s future relationship with COVID-19.